Cargando…

More Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain

Detalles Bibliográficos
Autor principal:	Curtiss, Frederic R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2006
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437638/ https://www.ncbi.nlm.nih.gov/pubmed/16792441 http://dx.doi.org/10.18553/jmcp.2006.12.4.343

Ejemplares similares

Montelukast: More than a Cysteinyl Leukotriene Receptor Antagonist?
por: Tintinger, Gregory R., et al.
Publicado: (2010)

The Effect of Combined Therapy ICS/LABA and ICS/LABA plus Montelukast in Patients with Uncontrolled Severe Persistent Asthma Based on the Serum IL-13 and FEV1
por: Janeva, Elena Jovanovska, et al.
Publicado: (2015)

The Editors Respond: The Diminishing Role of Montelukast in Asthma Therapy
por: Crownover, Brian K., et al.
Publicado: (2006)

Leukotrienes vs. Montelukast—Activity, Metabolism, and Toxicity Hints for Repurposing
por: Marques, Cátia F., et al.
Publicado: (2022)

Exercise-induced bronchoconstriction: The effects of montelukast, a leukotriene receptor antagonist
por: Kemp, James P
Publicado: (2009)

The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic
por: Aigner, Ludwig, et al.
Publicado: (2020)

Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease
por: Wallin, Johan, et al.
Publicado: (2021)

Role of Leukotrienes and Leukotriene Modifiers in Asthma
por: Montuschi, Paolo
Publicado: (2010)

Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity
por: Al-kuraishy, Hayder M., et al.
Publicado: (2021)

Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler
por: Price, David B., et al.
Publicado: (2016)

The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice
por: Michael, Johanna, et al.
Publicado: (2021)

Montelukast Inhibits Lung Cancer Cell Migration by Suppressing Cysteinyl Leukotriene Receptor 1 Expression In vitro
por: Chen, Yisheng, et al.
Publicado: (2023)

Beneficial effects montelukast, cysteinyl-leukotriene receptor antagonist, on renal damage after unilateral ureteral obstruction in rats
por: Otunctemur, Alper, et al.
Publicado: (2015)

Montelukast: its role in the treatment of childhood asthma
por: Harmanci, Koray
Publicado: (2007)

Asthma phenotypes: the intriguing selective intervention with Montelukast
por: Marcello, Cottini, et al.
Publicado: (2016)

Role of Montelukast in Asthma and Allergic rhinitis patients
por: Zuberi, Faisal Faiyaz, et al.
Publicado: (2020)

Analysis of the Effectiveness and Cost Benefit of Leukotriene Modifiers in Adults With Asthma in the Ohio Medicaid Population
por: Heaton, Pamela C., et al.
Publicado: (2006)

Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma
por: Beasley, Richard, et al.
Publicado: (2019)

Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management
por: Kaplan, Alan, et al.
Publicado: (2020)

LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes
por: Hizawa, Nobuyuki
Publicado: (2015)

Adipokines and Cysteinyl Leukotrienes in the Pathogenesis of Asthma
por: Coffey, Michael J., et al.
Publicado: (2015)

The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies
por: Marschallinger, Julia, et al.
Publicado: (2020)

Montelukast in acute asthma exacerbations: Interpreting too far??
por: Mittal, Saurabh, et al.
Publicado: (2017)

Budesonide/Fomoterol in combination with Montelukast in the treatment of Bronchial Asthma
por: Dai, Xiaoxia, et al.
Publicado: (2020)

Deprescribing montelukast in children with asthma: a systematic review
por: Dixon, Eleanor Grace, et al.
Publicado: (2022)

A multicenter, prospective, observational study on montelukast monotherapy or montelukast-based combinations treating cough variant asthma
por: Lin, Jiangtao, et al.
Publicado: (2020)

Use of ICS/LABA on Asthma Exacerbation Risk in Patients Within a Medical Group
por: Stanford, Richard H., et al.
Publicado: (2015)

EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
por: Buhl, Roland, et al.
Publicado: (2023)

Effects of oral cysteine leukotriene receptor antagonist-montelukast on adenoid lymphoid tissue: a histopathological study under light microscope
por: Wang, Zhengying, et al.
Publicado: (2023)

Asthma control in adolescents: role of leukotriene inhibitors
por: Giavi, Stavroula, et al.
Publicado: (2010)

170 Combination of a Nasal Antihistamine Olopatadine and A Leukotriene Receptor Antagonist Montelukast Sodium for the Treatment of Seasonal Allergic Patients not Currently Controlled on Monotherapy Intranasal Antihistamine or a Leukotriene Receptor Antagonist
por: Nsouli, Safa
Publicado: (2012)

Single Inhaler LABA/LAMA for COPD
por: Malerba, Mario, et al.
Publicado: (2019)

Evaluating the costs and benefits of marsh-management strategies while accounting for uncertain sea-level rise and ecosystem response
por: Propato, Marco, et al.
Publicado: (2018)

Suboptimally controlled asthma in patients treated with inhaled ICS/LABA: prevalence, risk factors, and outcomes
por: Zhang, Shiyuan, et al.
Publicado: (2023)

Exercise-induced asthma: critical analysis of the protective role of montelukast
por: Carver, Terrence W
Publicado: (2009)

Montelukast and budesonide combination for children with chronic cough-variant asthma
por: Wang, Xiu-ping, et al.
Publicado: (2018)

Role of Montelukast in Improving Quality of Life in Patients with Persistent Asthma
por: Ikram, Ayesha, et al.
Publicado: (2019)

The synergistic effects of clopidogrel with montelukast may be beneficial for asthma treatment
por: Trinh, Hoang Kim Tu, et al.
Publicado: (2019)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
por: Singh, Dave, et al.
Publicado: (2019)

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
por: Rodrigo, Gustavo J, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_placdm70s68a7diqk2nk9rubrp